PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 65 filers reported holding PROTAGONIST THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,004,703 | +22.4% | 60,234 | +102.6% | 0.00% | +50.0% |
| Q2 2023 | $821,060 | +20.4% | 29,727 | +0.2% | 0.00% | 0.0% |
| Q1 2023 | $682,019 | +33.6% | 29,653 | -36.6% | 0.00% | +100.0% |
| Q4 2022 | $510,675 | +50967.5% | 46,808 | +167071.4% | 0.00% | – |
| Q2 2022 | $1,000 | -100.0% | 28 | -100.0% | 0.00% | -100.0% |
| Q3 2021 | $2,326,000 | -16.4% | 131,282 | +111.7% | 0.00% | -20.0% |
| Q2 2021 | $2,783,000 | +221.0% | 62,015 | +44.2% | 0.01% | +150.0% |
| Q4 2020 | $867,000 | +43250.0% | 42,992 | +40844.8% | 0.00% | – |
| Q3 2020 | $2,000 | -50.0% | 105 | -65.5% | 0.00% | – |
| Q2 2019 | $4,000 | +100.0% | 304 | +74.7% | 0.00% | – |
| Q1 2019 | $2,000 | -97.6% | 174 | -98.6% | 0.00% | – |
| Q2 2018 | $85,000 | -84.5% | 12,682 | -80.2% | 0.00% | -100.0% |
| Q1 2018 | $549,000 | +51.7% | 63,921 | +266.8% | 0.00% | +100.0% |
| Q4 2017 | $362,000 | – | 17,425 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $67,646,434 | 21.00% |
| COWEN AND COMPANY, LLC | 1,657,551 | $45,781,558 | 3.80% |
| Kynam Capital Management, LP | 975,298 | $26,937,731 | 3.70% |
| BVF INC/IL | 3,775,900 | $104,290,358 | 2.91% |
| RTW INVESTMENTS, LP | 5,415,514 | $149,576,497 | 2.85% |
| Cormorant Asset Management, LP | 1,500,000 | $41,430,000 | 2.32% |
| Ghost Tree Capital, LLC | 225,000 | $6,214,500 | 2.05% |
| 683 Capital Management, LLC | 814,000 | $22,482,680 | 1.62% |
| Perceptive Advisors | 1,469,761 | $40,594,799 | 1.18% |
| Artia Global Partners LP | 112,340 | $3,102,831 | 1.07% |